Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PD1 & PDL1 inhibitors for mUC, where are we?

Petros Grivas • 30 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, outlines efficacy and safety data on the use of PD1 & PDL1 inhibitors in the treatment of metastatic urothelial cancer (mUC) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Petros Grivas

1:08
Phase III clinical trials exploring targeted combination therapies for patients with UC
Petros Grivas • 20 Oct 2023
1:39
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
Petros Grivas • 20 Oct 2023
2:21
How junior physicians can develop a successful career in medical oncology
Petros Grivas • 20 Oct 2023
1:54
Innovations in treatment options for patients with BCG-unresponsive urothelial carcinoma
Petros Grivas • 20 Oct 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals